Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2022 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022
May 26, 2022 17:15 ET
|
Oncternal Therapeutics
Updated MCL and CLL data from the CIRLL study are encouraging and continue to improveORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27 evaluable patients) for patients with MCL...
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results
May 05, 2022 16:01 ET
|
Oncternal Therapeutics
Global registrational Phase 3 study, ZILO-301, of zilovertamab in patients with MCL on track to be initiated in Q3 2022Presenting interim clinical data update from the ongoing Phase 1/2 clinical trial...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2022 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2022 Financial Results
April 28, 2022 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma
April 13, 2022 08:30 ET
|
Oncternal Therapeutics
Discontinued enrollment of Phase 1/2 trial of ONCT-216 in Ewing sarcomaResources will be primarily reallocated to our zilovertamab global registrational Phase 3 study ZILO-301, which is expected to be...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2022 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, April 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2021 Financial Results
March 10, 2022 16:01 ET
|
Oncternal Therapeutics
Reached consensus with the FDA on the design and major details of the global Phase 3 Study ZILO-301 to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinib, which is on...
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results
March 07, 2022 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2022 17:00 ET
|
Oncternal Therapeutics
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...